Literature DB >> 1993498

Prognosis of Wilsonian chronic active hepatitis.

M L Schilsky1, I H Scheinberg, I Sternlieb.   

Abstract

Twenty of 320 patients with Wilson's disease initially presented with chemical and laboratory features of chronic active hepatitis, confirmed histologically in 17. When first seen, cirrhosis was present in all 20 and was complicated by ascites and/or jaundice in 11. Within 1 week to 8 years of the onset of over liver disease the diagnosis of Wilson's disease was established, and treatment with D-penicillamine was promptly initiated in 19 patients. One man refused treatment and died 4 months later. Treated patients received D-penicillamine or trientine for a total of 264 patient-years (median, 14 patient-years). Abnormal water retention, for which salt restriction and diuretics were added to penicillamine or trientine, disappeared in all but 1 of the patients so affected. Symptomatic improvement and virtually normal levels of serum albumin, bilirubin, aspartate aminotransferase, and alanine aminotransferase followed within 1 year in the majority of subjects. One woman died after 9 months of treatment. Two patients, who became noncompliant with the therapeutic regimen after 9 and 17 years of successful pharmacological treatment, required liver transplants. These results indicate that the prognosis of specifically treated Wilsonian chronic active hepatitis is very good in spite of the presence of cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993498     DOI: 10.1016/0016-5085(91)80023-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

Review 1.  Autoimmune hepatitis.

Authors:  E A Roberts
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

2.  Wilson's Disease.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

Review 3.  Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature.

Authors:  V Ferlan-Marolt; S Stepec
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

4.  Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period.

Authors:  A Członkowska; B Tarnacka; T Litwin; J Gajda; M Rodo
Journal:  J Neurol       Date:  2005-03-02       Impact factor: 4.849

5.  Liver transplantation in Wilson's disease: Single center experience from Saudi Arabia.

Authors:  Musthafa Chalikandy Peedikayil; Hamad Ibrahim Al Ashgar; Abdullah Al Mousa; Mohammed Al Sebayel; Khalid Al Kahtani; Faisal Aba Alkhail
Journal:  World J Hepatol       Date:  2013-03-27

Review 6.  Disorders of metal metabolism.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-12-18

7.  Cirrhosis in Wilson Disease is characterized by Impaired Hepatic Synthesis, Leukopenia and Thrombocytopenia.

Authors:  Hao-Jie Zhong; Ping Xiao; Da Lin; Hui-Min Zhou; Xing-Xiang He
Journal:  Int J Med Sci       Date:  2020-05-29       Impact factor: 3.738

8.  The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease.

Authors:  Emilie Glavind; Daniel N Gotthardt; Jan Pfeiffenberger; Thomas Damgaard Sandahl; Teodora Bashlekova; Gro Linno Willemoe; Jane Preuss Hasselby; Karl Heinz Weiss; Holger Jon Møller; Hendrik Vilstrup; William M Lee; Michael L Schilsky; Peter Ott; Henning Grønbæk
Journal:  Orphanet J Rare Dis       Date:  2020-07-02       Impact factor: 4.123

9.  Designing Clinical Trials in Wilson's Disease.

Authors:  Peter Ott; Aurélia Poujois; Thomas Damgaard Sandahl; Karl Heinz Weiss; Peter Ferenci; Michael L Schilsky; Aftab Ala; Frederick K Askari; Anna Czlonkowska; Ralf-Dieter Hilgers; Eve A Roberts
Journal:  Hepatology       Date:  2021-10-05       Impact factor: 17.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.